Glenmede Trust’s Aspire Biopharma ASBP Stock Holding History

Glenmede Trust’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-82	Closed	-$985K	–	1343
2022 Q2	$985K	Buy	+82	New	+$982K	0.01%	687

Other funds holding ASBP

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Glenmede Trust's ASBP Position: Q3 2022 in Review

Glenmede Trust sold out of Aspire Biopharma (ASBP) in Q3 2022, closing a stake of 82 shares — an estimated $985K sold.

Glenmede Trust first reported a position in ASBP in Q2 2022 and held it in 1 quarter. The position peaked at $985K in Q2 2022. 59 funds tracked by Wall St. Rank hold ASBP as of Q3 2022.

Glenmede Trust reported no remaining Aspire Biopharma position as of Q3 2022 after selling out during the quarter.
Glenmede Trust sold 82 Aspire Biopharma shares in Q3 2022, an estimated $985K.
Glenmede Trust first reported a position in Aspire Biopharma in Q2 2022 and held it in 1 quarter.
Glenmede Trust's Aspire Biopharma position peaked at $985K in Q2 2022.
59 funds tracked by Wall St. Rank held Aspire Biopharma as of Q3 2022.

Based on Glenmede Trust's 13F filing for Q3 2022, filed 16 Nov 2022.